Monoclonal 18A4 Against AGR2 Inhibit Human Breast Adenocarcinoma Cell Growth And Migration

Monoclonal antibody is playing a more and more important role in the diagnosis and treatment of cancer. Specifically, secretory antigens which promote tumor growth and metastasis is emerging as important targets for antibodies-based anti-cancer therapy.Recent discoveries reveal that Anterior Gradient-2(AGR2)is overexpressed in a series of adenocarcinoma, and not only expressed in the cytoplasm but also expressed in the culture supernatant of cancer cells. Moreover, there is evidence indicating that extracellular AGR2 promotes cell growth and migration. Thus, AGR2 might be a promising anti-cancer target for antibodies-based therapy.This thesis was focusing on the study of the feasibility of anti-cancer therapy against AGR2 as the target. The study first established Anti-AGR2 hybridoma 18A4 cell line, and found monoclonal antibody AGR2 can inhibit the growth of MCF-7 cell and T47D cell and migration of T47D cell.